Pharmaceutical companies and their agencies are "mulling" over amongst
themselves how the drug industry should engage consumers and physicians
via social media without violating FDA regulations. They are struggling
because the FDA has never issued clear guidelines for how it may
regulate the industry use of social media in the future. Many have
called upon the FDA to issue such guidelines.
Shouldn't we make
sure that when it comes time for the FDA to actually create a guidance
document on social media that it does it with input from ALL
This article will present a review of this issue
based upon input received from experts and respondents to the "Should
FDA Convene a Public Hearing on Use of Social Media by Pharma?" survey
hosted by Pharma Marketing News
starting on April 2, 2009. Also included in a review of an ePharma
Pioneer Club roundtable discussion on what it's going to take to enable
pharmaceutical marketers to engage in social networks without fear of
adverse event reporting and other regulatory, corporate, and cultural
Topic headings include:
Read this article now. It's FREE...
- The 14 Letters were No April Fools' Joke!
- An Unmet Need for Regulatory Guidance
- FDA, Tear Down This Wall!
- Call for Public Hearing
- Lessons Learned from the "One-Click Rule"
- Lack of Knowledge is No Excuse
- There is a Precedent
- A Clear Path Needed
- Survey Results
- A Moving Target
- The Views of Skeptics
- What Good Can Come from a Public FDA Hearing on Social Media?
- Alternatives to a Public Hearing
Download PDF file